证券代码：301330 证券简称：熵基科技 公告编号：2025-064 熵基科技股份有限公司 关于注销及开立闲置募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 三、投资风险及风险控制措施 （一）投资风险分析 1、虽然投资产品均经过严格的评估，但金融市场受宏观经济影响，不排除 该项投资受到市场波动的影响。 为提高闲置募集资金使用效率，合理利用暂时闲置的募集资金，增加公司投 资收益和股东回报，熵基科技股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第十一次会议和第三届监事会第十次会议，审议通过 了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司 使用不超过人民币 80,000 万元（含本数）的部分暂时闲置募集资金（含超募资 金）进行现金管理，该使用额度及授权的有效期自公司董事会审议通过之日起 12 个月内有效，并在上述额度内滚动使用。具体内容详见公司于 2024 年 8 月 30 日 在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于使用部分暂时闲置 ...

Group 1 - A total of 24 companies were investigated by institutions on June 25, with 17 companies specifically targeted by funds [1][2] - The most popular company among funds was Botao Bio, which had 21 participating funds, followed by Sanfu Outdoor and Entropy Technology with 7 and 6 funds respectively [1][2] - The companies investigated belong to 12 different industries, with the textile and apparel, and pharmaceutical and biotechnology sectors having the most companies, each with 3 stocks listed [1] Group 2 - Among the companies investigated, 3 had a total market capitalization exceeding 50 billion yuan, while 13 had a market cap below 10 billion yuan [1] - In terms of market performance, 9 stocks among the investigated companies saw an increase in the last 5 days, with Haike Xinyuan, Bai'ao Intelligent, and Ganfeng Lithium leading with increases of 50.83%, 10.42%, and 5.88% respectively [1][2] - Conversely, 8 stocks experienced declines, with Mankalon, Botao Bio, and China Merchants Energy showing the largest drops of 7.94%, 5.35%, and 4.76% respectively [1][2]

Group 1: Company Overview and Business Strategy - The company aims to enhance market competitiveness through AI technology and brand influence, targeting revenue growth aligned with high equity incentive goals [2] - Focus on optimizing product and business structure, controlling costs, and improving operational efficiency to achieve performance growth [2] Group 2: Brain-Machine Interface (BMI) Technology - The company is exploring non-invasive BMI technology, particularly in the fields of elderly care, healthcare, and education [2][4] - Utilizes multi-modal data fusion technology ("EEG + EOG + EMG") to overcome precision limitations of traditional single-modal devices [2] Group 3: Applications in Education - Launching non-invasive brain-computer interface products aimed at enhancing focus among youth through interactive games and real-time EEG signal collection [3] Group 4: Partnerships and Collaborations - Established a long-term partnership with Workday to provide payroll calculation services for various sectors, enhancing operational efficiency for clients [5] Group 5: Mergers and Acquisitions - Ongoing audit of financial indicators related to the acquisition of "Longzhiyuan," with expectations of synergistic effects in product, technology, and market resources [6] Group 6: Ralvie AI Business Model - Ralvie AI focuses on work management and operational efficiency, quantifying employee work time and efficiency as a basis for performance evaluation [7] Group 7: Mars Wisdom Solutions - Mars Wisdom leverages advanced AI technologies to address semantic understanding, visual analysis, and data retrieval challenges, integrating with existing business platforms for enhanced service delivery [8] Group 8: Investor Relations Activity - The investor relations activity did not involve any undisclosed significant information [9]

A股市场热点不断，近期，"脑机接口"概念火了。 21世纪经济报道记者注意到，在上周大涨之后，6月23日，脑机接口板块继续上扬，塞力医疗 （603716）（603716.SH）"10CM"涨停，三博脑科（301293）（301293.SZ）涨幅超5%，佳禾智能 （300793）（300793.SZ）、麒盛科技（603610）（603610.SH）涨幅3%以上、诚益通（300430） （300430.SZ）、狄耐克（300884）（300884.SZ）、乐普医疗（300003）（300003.SZ）、熵基科技 （301330）（301330.SZ）涨幅2%以上。 与此同时，投资者涌向上市公司互动平台，密集询问公司脑机接口相关布局。从机构调研的角度看，近 两个月已有不少机构提前嗅到了相关机遇，了解脑机接口相关业务。 就脑机接口的产业链机遇而言，浙商证券（601878）指出，产业应用上，该市场仍以医疗为主。未来在 教育、游戏、智能家居等领域的应用占比将逐步提升。软件层面，人工智能技术的高速发展将为脑机接 口带来更多的创新机会；硬件层面，更高精度的传感器正在被开发，设备越来越轻便、便携，侵入性与 人体的兼容性正在持续改 ...

证券代码：301330 证券简称：熵基科技 公告编号：2025-062 熵基科技股份有限公司 关于持股 5%以上股东权益变动触及 1%整数倍的公告 股东深圳精英士君投资企业（有限合伙）及深圳精英和义投资企 业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 熵基科技股份有限公司（以下简称"公司"或"熵基科技"）于 2025 年 3 月 17 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股 份计划预披露公告》，公司持股 5%以上的股东深圳精英士君投资企业（有限合 伙）（以下简称"精英士君"）及深圳精英和义投资企业（有限合伙）（以下简 称"精英和义"）计划自减持计划预披露公告之日起十五个交易日后的三个月内， 分别以集中竞价和/或大宗交易方式减持公司股份不超过 2,886,600 股（不超过公 司剔除回购专用账户中股份数量后总股本的 1.4873%）。本次减持计划实施前， 精英士君持有公司股份 14,038,400 股，占公司总股本的 7.1511%；精英和义 ...

证券代码：301330 证券简称：熵基科技 公告编号：2025-063 熵基科技股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开第三 届董事会第十七次会议、2025 年 5 月 15 日召开 2024 年年度股东大会，审议通 过了《关于变更注册资本及修改〈公司章程〉并办理工商登记变更手续的议案》， 具体内容详见公司于 2025 年 4 月 23 日在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于变更注册资本及修改〈公司章程〉并办理工商登记变更手续的公告》 （公告编号：2025-048）。 近日，公司完成了工商变更登记及修订后的《公司章程》备案，取得了东莞 市市场监督管理局核发的《营业执照》。现将相关情况公告如下： 一、公司注册资本变更相关情况 公司于 2025 年 6 月 4 日实施完成 2024 年年度权益分派方案，本次实施的权 益分派方案为：以截至 2025 年 6 月 3 日公司总股本 196,312,325 股扣除公司回购 专户中已回购股份 1,116,200 股后的股本 195,196,125 股为基数，向全体股东每 10 股转增 2 股。本次权益 ...

Group 1 - The core viewpoint of the news is that Shangji Technology (熵基科技) is currently experiencing a decline in stock price, with a closing price of 24.74 yuan and a drop of 5.28%, indicating it is in a state of post-IPO underperformance [1] - Shangji Technology was listed on the Shenzhen Stock Exchange's ChiNext board on August 17, 2022, with an initial issuance of 37.123 million shares, accounting for 25% of the total post-issue share capital, at an issue price of 43.32 yuan per share [1][2] - On its first trading day, the stock reached a peak price of 68.00 yuan but has since experienced a downward trend [2] Group 2 - The total amount raised by Shangji Technology during its IPO was 1.608 billion yuan, with a net amount of 1.457 billion yuan after deducting issuance costs, which was 147.64 million yuan more than the original plan [2] - The funds raised are intended for various projects, including the construction of a production base in Tangxia, a mixed biometric IoT smart industry base, a manufacturing facility in the United States, a research and development center, and a global marketing service network [2] - The total issuance costs (excluding VAT) amounted to 150.87 million yuan, with UBS Securities receiving 116.62 million yuan as underwriting and sponsorship fees [2] Group 3 - On May 25, 2023, Shangji Technology announced a dividend plan, proposing a stock bonus of 3 shares for every 10 shares held and a cash dividend of 3.5 yuan (pre-tax) [2] - The ex-dividend date was set for May 31, 2023, with the share registration date on May 30, 2023 [2] - At the 2024 annual general meeting scheduled for May 15, 2025, the company plans to distribute cash dividends of 5 yuan (including tax) for every 10 shares and to increase capital by transferring 2 shares for every 10 shares held, without issuing new shares [3]

Group 1 - The brain-computer interface sector has experienced a significant surge, with companies like Innovation Medical (002173) hitting the daily limit up [1] - Other companies such as Beikang, Aipeng Medical (300753), Nanjing Panda (600775), Entropy Technology (301330), and Sanbo Brain Science (301293) have also seen notable increases in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and activity [1]

Group 1: Business Overview - The company's main business is the smart space sector, accounting for 75.62% of its main business revenue in 2024 [2] - The sales model combines distribution and direct sales, with distribution revenue making up 69.36% of main business revenue [2] Group 2: Technology and R&D - The company focuses on non-invasive brain-machine interface technology, utilizing scalp electrodes and flexible sensors to collect EEG signals [2] - Applications include educational tools for children and preventive interventions in elderly care, aiding in early detection of cognitive decline [2] Group 3: Impact of External Factors - The current U.S. tariff policy has a minimal impact on the company, as software hosting services are not affected by import tariffs [3] - Hardware products are imported from Thailand, which mitigates short-term impacts from U.S. tariffs [3] Group 4: Growth and Strategic Goals - The company aims to achieve high stock incentive assessment targets by leveraging AI technology and enhancing market competitiveness [3] - Efforts include optimizing product and business structures, controlling costs, and increasing investment in promising innovation areas [3] Group 5: M&A Activity - The financial indicators for the acquisition target "Longzhiyuan" are currently under audit, with due diligence progressing normally [3] - Successful acquisition is expected to enhance product layout and profitability through synergies in products, technology, and market resources [3]

Core Points - The stock price of Entropy Technology (301330) increased by 2.36% to 29.55 yuan as of May 30, 2025, with a market capitalization of 5.801 billion yuan [1] - In 2024, the company achieved a revenue of 199.12004 billion yuan, a year-on-year increase of 1.07%, and a net profit of 18.3046 billion yuan, up 3.26% [2][5] - For the first quarter of 2025, the company reported a revenue of approximately 413.68 million yuan, a 3.50% year-on-year growth, and a net profit of approximately 29.46 million yuan, reflecting an 11.88% increase [2][5] - As of March 31, 2025, the total number of ordinary shareholders was 17,648, and the company's share capital increased from 196,237,363 shares to 196,312,325 shares [3][5] - The company announced a profit distribution plan for 2024, proposing a cash dividend of 5 yuan per 10 shares and a capital reserve increase of 2 shares for every 10 shares [4][5] - The company approved the 2025 restricted stock incentive plan and employee stock ownership plan on January 23, 2025 [4][5]